Loading people...
Denis Patrick is the Vice President and Managing Partner at Pfizer Ventures, as well as the Head of Partnering Innovation at Pfizer, based in Cambridge, Massachusetts. Before transitioning to corporate venture capital, he spent over a decade in oncology research at GlaxoSmithKline and served as Head of Oncology Licensing for Worldwide R&D at Pfizer from 2010 to 2018. During his tenure in licensing, he oversaw major pharmaceutical transactions including the strategic acquisitions of Medivation and BIND Therapeutics. In 2018, Patrick was named Managing Partner concurrent with Pfizer's $600 million commitment to early-stage biotech investments, subsequently leading a $15 million funding round for MISSION Therapeutics in 2020. Holding a doctorate in biochemistry from the University of Pennsylvania, he currently focuses on deploying equity capital into emerging life sciences companies specializing in oncology, neuroscience, and novel drug discovery platforms.
Denis Patrick holds the significant position of Vice President at Pfizer Venture Investments (PVI), the dedicated corporate venture capital arm of Pfizer Inc. In this capacity, he plays a crucial role in shaping the future of healthcare by identifying, evaluating, and investing in promising early-stage and growth-stage companies. PVI's mission is to support ventures that are developing innovative science and technologies aligned with Pfizer's strategic interests, ultimately aiming to deliver transformative medicines and healthcare solutions to patients worldwide.
At Pfizer Venture Investments, Denis Patrick's responsibilities encompass a broad spectrum of activities essential to successful venture capital. He is deeply involved in deal sourcing, actively seeking out companies that are pioneering advancements in areas such as novel therapeutics, drug discovery platforms, digital health solutions, and other critical life science technologies. His work includes rigorous due diligence, assessing the scientific merit, market potential, and operational viability of prospective investments. Furthermore, Denis contributes to the strategic management of PVI's diverse portfolio, working closely with invested companies to help them achieve their milestones and accelerate their growth.
Denis Patrick's career background likely reflects a strong foundation in both scientific understanding and financial acumen, a common profile for leaders in corporate venture capital within the life sciences sector. Professionals in this role often possess advanced degrees in scientific disciplines, medicine, or business, coupled with extensive experience in venture capital, corporate development, or the pharmaceutical industry itself. This blend of expertise enables him to effectively bridge the gap between cutting-edge scientific innovation and sound investment strategy.
While specific notable investments are not publicly detailed, Denis Patrick's involvement at Pfizer Venture Investments means he is actively contributing to a portfolio that includes companies developing breakthrough treatments for oncology, immunology, rare diseases, and infectious diseases, among others. PVI typically invests in companies that are at the forefront of scientific discovery, leveraging new modalities and technologies to address unmet medical needs. His work is vital in fostering an ecosystem of innovation that can bring new therapies and health solutions from concept to reality, reinforcing Pfizer's commitment to advancing global health. His strategic insights and investment decisions are key to PVI's success in identifying and nurturing the next generation of healthcare leaders.
Denis Patrick is the Vice President at Pfizer Venture Investments, the corporate venture capital arm of Pfizer Inc. He is responsible for identifying, evaluating, and investing in innovative life science and healthcare technology companies.
Denis Patrick, through Pfizer Venture Investments, invests in early-stage and growth-stage companies focused on biotechnology, novel therapeutics, digital health, and other life science technologies that align with Pfizer's strategic interests.
Denis Patrick works as Vice President at Pfizer Venture Investments, which is the corporate venture capital division of Pfizer Inc.
